BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint  by Dierov, Jamil et al.
A R T I C L E
BCR/ABL translocates to the nucleus and disrupts an ATR-
dependent intra-S phase checkpoint
Jamil Dierov, Raia Dierova, and Martin Carroll*
Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104
*Correspondence: carroll2@mail.med.upenn.edu
Summary
Chronic myelogeneous leukemia (CML) is a two-stage disease associated with expression of the BCR/ABL tyrosine kinase
protein. However, whether BCR/ABL expression directly causes blast crisis, and if so by what mechanism, is unknown.
We have found that BCR/ABL translocates from the cytoplasm to the nucleus after genotoxic stress. Furthermore, BCR/
ABL increases DNA double-strand damage after etoposide treatment and leads to a defect in an intra-S phase checkpoint,
causing a radioresistant DNA synthesis (RDS) phenotype. In the nucleus, BCR/ABL associates with the ataxia-telangiectasia
and rad 3-related protein (ATR) and disrupts ATR-dependent signal transduction. Overexpression of ATR in a BCR/ABL-
expressing cell line corrects the DNA damage phenotype. These results demonstrate a nuclear role for BCR/ABL in altering
the cellular response to DNA damage.
Introduction increased growth rate of CML stem cells would lead to an
increase in the accumulation of DNA damage; however, the
increase in the growth rate of CML versus normal hematopoieticChronic phase CML is a clonal, hyperproliferative disease with
an overproduction of white blood cells that retain the capacity stem cells is minimal, suggesting that this explanation is inade-
quate. Deutsch et al. (2001, 2003) recently suggested thatto differentiate. However, all patients with CML will advance in
3–5 years to blast crisis, which is characterized by a block in stable expression of BCR/ABL alters the expression of the DNA
repair enzyme, DNA-PKcs, a PIKK family kinase. Interestingly,differentiation and resistance to chemotherapy. Blast crisis is
associated with the acquisition of additional genetic damage the authors found that the human cell line, UT-7, expressing
transduced BCR/ABL, had increased chromosomal aberrationsincluding chromosomal translocations and deletions (Ahuja et
al., 1989; Griesshammer et al., 1997). Whereas recent work has compared to nontransduced cells after -irradiation. This result
is consistent with the hypothesis that BCR/ABL induces grossestablished that the BCR/ABL oncogene is sufficient to cause
chronic phase CML (Daley et al., 1990; Druker et al., 2001; Pear chromosomal instability, but a mechanism whereby BCR/ABL
would affect DNA-PKcs expression was not proposed. Anotheret al., 1998), there is relatively little information about why CML
cells inevitably evolve to blast crisis. BCR/ABL is a well-studied group, using a yeast two-hybrid approach, found that BCR/ABL
can associate with the xeroderma pigmentosum group B proteintyrosine kinase oncogene that stimulates dysregulated cellular
proliferation (Salesse and Verfaillie, 2002). The translocation (XPB), but XPB deficiency leads to a nucleotide excision repair
defect that would lead to the formation of point mutations, notleads to fusion of an oligomerization domain of BCR with the
kinase and signaling domains of the c-ABL protein. Work from chromosomal translocations (Takeda et al., 1999). Interestingly,
Slupaniek et al. have studied whether BCR/ABL directly leadsmany groups has shown that BCR/ABL is a constitutively oligo-
merized and activated tyrosine kinase that activates multiple to the chemoresistance seen in blast crisis. They have shown
that BCR/ABL upregulates STAT5 signaling, leading to in-signal transduction pathways including STAT, Ras, and PI3 ki-
nase (Gishizky and Witte, 1992; Konopka et al., 1984). However, creased expression of Rad51 and a modification of homologous
recombination (HR) repair (Slupianek et al., 2001). The authorsactivation of cytoplasmic signaling proteins does not appear to
explain the progression to blast crisis by itself. have proposed that BCR/ABL-expressing cells repair their DNA
damage more rapidly than control cells and that this results inPrevious work on the role of BCR/ABL in inducing blast
crisis has been limited because of the absence of a reproducible chemoresistance. It is unclear if the described increased rate
of homologous recombination repair is “error prone,” leadinganimal model of blast crisis. It has been proposed that the
S I G N I F I C A N C E
CML is a two-stage disease in which the initial hyperproliferative phase is followed by a second lethal phase designated blast crisis.
Extensive work has demonstrated that the BCR/ABL oncogene directly causes increased proliferation of cells and leads to myeloid
hyperproliferation. However, it has never been clear why all patients with CML progress to blast crisis. Here, we show that the BCR/
ABL oncogene has a second previously undescribed mechanism. After DNA damage, BCR/ABL moves from the cytoplasm to the
nucleus. In the nucleus, BCR/ABL binds to a critical cell cycle checkpoint regulator, ATR, and blocks its function, leading to increased
DNA damage in the BCR/ABL-expressing cells. This impaired DNA repair may cause BCR/ABL-expressing cells to accumulate further
genetic damage, leading to blast crisis.
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to genomic instability. Thus, although several suggestions have F3 pTET-ON p210 cells (a kind gift of Dr. George Daley, MIT,
been made about how BCR/ABL could induce chromosomal Cambridge, MA) (Klucher et al., 1998). We confirmed (Figure
instability, it is still unclear if BCR/ABL itself is responsible for 1A) that exposure of cells to doxycycline induces expression
chromosomal instability leading to blast crisis. of p210 BCR/ABL over 24 hr and that cells grew at nearly
An alternative approach to understanding the oncogenic equivalent rates in the presence of interleukin 3 (IL3) or doxycy-
role of BCR/ABL has been proposed based on the cellular ho- cline (Figure 1B). Initially, we used cell survival as a surrogate
molog of BCR/ABL, c-ABL. c-ABL is a tyrosine kinase that for DNA damage. In general, in cells with equivalent apoptotic
usually resides in the nucleus but can translocate to the cyto- responses, increased DNA damage leads to increased apopto-
plasm where it may regulate cell adhesion (Taagepera et al., sis. However, cells grown in IL3 or in doxycycline for at least
1998; Van Etten et al., 1989; Wetzler et al., 1993). In the nucleus, 24 hr showed only minor differences in cytotoxicity after treat-
c-ABL is activated in response to DNA damage. After DNA ment with several chemotherapeutic agents (Figure 1C and data
damage, c-ABL binds to the ataxia-telangiectasia mutant (ATM) not shown). With etoposide, as shown, there is a statistically
protein as well as to the p53 homolog, p73 (Agami et al., 1999; significant enhancement of toxicity in BCR/ABL-expressing
Baskaran et al., 1997; Gong et al., 1999; Kharbanda et al., 1998; cells, but it is unclear if this difference is of major biologic sig-
Shafman et al., 1997; Wang, 2000; White and Prives, 1999). c-ABL nificance, as it changes the level at which 50% of the cells
can phosphorylate p73 and promote apoptosis after DNA dam- are killed (ED50) by less than 1 M. Cells deprived of IL3 and
age, although how essential a role this plays in the DNA damage doxycycline showed increased cell death as expected (Figure
response is unclear. It has been postulated that BCR/ABL may 1B, open boxes). In order to examine DNA damage directly, we
usurp or disrupt some of the functions of c-ABL but this has next used the comet assay (Singh et al., 1988). The comet assay
never been documented. BCR/ABL, which is normally localized is a single cell gel electrophoresis assay. After treatment with
in the cytoplasm (Wetzler et al., 1993), can be found in the a DNA-damaging agent, cells are implanted in agarose and
nucleus after treatment of cells with the ABL kinase inhibitor, lysed in alkaline lysis buffer that both disrupts the cell membrane
STI571, and the nuclear export inhibitor, leptomycin B (LMB) and allows damaged DNA to uncoil. Cells are then placed in
(Vigneri and Wang, 2001), but the physiologic significance of an electric field and damaged DNA migrates, forming a “tail.”
these conditions is unclear. In particular, there has been no The undamaged DNA does not migrate, forming the comet
previous demonstration of a direct role of BCR/ABL in modifying “head.” The length and intensity of the comet tail is proportional
nuclear signal transduction pathways. to the amount of DNA damage (Figure 1D). Cells were incubated
In order to study the mechanism whereby BCR/ABL could with etoposide for varying periods of time as shown (Figure 1E).
affect DNA damage and repair, we have used the tetracycline- At indicated time points, cells were harvested and processed
inducible BCR/ABL-expressing cell line Ba/F3 pTET-ON p210 for analysis using the comet assay. Olive tail moment (% DNA
(Klucher et al., 1998). The use of a tetracycline-inducible system in comet tail  distance of center of gravity of DNA from the
allows for comparison of isogenic cells that do or do not express head) was calculated for 50–100 cells and results averaged. Ba/
BCR/ABL. We have examined cells primarily after genotoxic F3 pTET-ON p210 cells growing in IL3 alone (white bars) had
stress induced by the topoisomerase 2 inhibitor etoposide in a time-dependent increase in DNA damage (Figure 1E) while in
order to amplify possibly small differences in the response to the presence of etoposide. After a 2 hr exposure to etoposide,
DNA damage. Etoposide has been recently found to induce an cells were washed and replated in media free of drug for 90
ataxia-telangiectasia and rad 3-related (ATR) dependent DNA min. The majority of the DNA damage was repaired within 90
repair process (Costanzo et al., 2003). Here we report that BCR/ min (Figure 1E, repair), and all DNA double-strand breaks were
ABL-expressing cells have an increase in DNA double-strand
resolved by 24 hr (data not shown). When cells were treated
breaks and a radioresistant DNA synthesis (RDS) phenotype
with doxycycline to induce BCR/ABL in the absence (striped
that results from disruption of the intra-S phase checkpoint after
bars) or presence (black bars) of IL3, the amount of DNA double-treatment with etoposide. Furthermore, BCR/ABL translocates
strand breaks was increased at each time point. Curiously, de-rapidly to the nucleus after etoposide-induced DNA damage.
spite this increased DNA damage, BCR/ABL-expressing cellsTranslocation is completely reversible after removal of the DNA-
were able to repair DNA damage quickly and completely (Figuredamaging agent. In the presence of etoposide, BCR/ABL, like
1E, repair), suggesting that the role of BCR/ABL in altering DNAc-ABL, associates with ATM but does not disrupt the function
repair is reversible. Overall, this experiment demonstrates thatof ATM. In contrast, BCR/ABL disrupts the function of the ATM
BCR/ABL expression leads to increased DNA damage afterhomolog, ATR, as characterized by the lack of phosphorylation
treatment of cells with etoposide.of Chk1 and by the inability of BCR/ABL-expressing cells to
To compare BCR/ABL-induced effects on DNA double-inactivate the cdc7/Dbf4 regulatory kinase after treatment with
strand breaks to known mutants with an effect on DNA repair,etoposide. Overexpression of ATR in a BCR/ABL-expressing
we have used fibroblast cell lines (Figure 1F). DNA double-cell line leads to the appropriate activation of Chk1 after DNA
strand breaks were again induced by etoposide. We compareddamage and a block in the DNA damage phenotype induced
NIH 3T3 cells to 3T3 cells stably expressing BCR/ABL (3T3 BCR/by BCR/ABL. Taken together, these results show that BCR/ABL
ABL) and to ATM-deficient fibroblasts. As expected, etoposideexpression inhibits activation of ATR after DNA damage and
induced DSB in NIH 3T3 cells and these breaks were rapidlyalters the cellular response to DNA damage.
repaired (Figure 1F, white bars). ATM-deficient fibroblasts suf-
fered increased DNA damage from the same dose of etoposide,Results
as expected (Figure 1F, gray bars). DNA repair was still rapid
in ATM-deficient cells, and all of the DNA damage was repairedBCR/ABL increases DNA double-strand breaks
by 24 hr after this short treatment with etoposide. ConsistentTo determine how BCR/ABL would affect the induction of DNA
damage and the regulation of DNA repair, we have used Ba/ with the results above, BCR/ABL-expressing cells incurred sig-
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Figure 1. BCR/ABL increases DNA double-strand
breaks
A: Ba/F3 pTET-ON p210 cells were grown in IL3
alone (lane 1) or washed free of IL3 and grown in
doxycycline alone for the indicated times. Cells
were lysed and lysates analyzed by Western blot
for the presence of BCR/ABL.
B: Cells were again grown in IL3 (open triangle),
in doxycycline to induce BCR/ABL (closed
squares), or in the absence of IL3 and doxycy-
cline (open circles). Cell number was deter-
mined by trypan blue exclusion.
C: Ba/F3 pTET-ON p210 cells were incubated in
the presence of IL3, the presence of doxycycline
(BCR/ABL) or in the absence of IL3 and doxycy-
cline. Cells were treated with varying concentra-
tions of etoposide for 48 hr and relative cell sur-
vival assayed using the XTT assay. Data in B and
C is from 3 separate experiments.
D: Ba/F3pTET-ON p210 cells were treated for 1 hr
with no drug or etoposide at indicated concen-
tration and analyzed as described in Experimen-
tal Procedures. Photomicrographs of individual
cells stained with propidium iodide are shown.
E: Ba/F3 pTET-ON p210 cells were grown under
indicated conditions (BCR/ABL), treated with
etoposide, and analyzed using the comet assay.
For each condition, 50–100 cells were analyzed
and mean  standard deviation calculated.
F: 3T3 cells, 3T3 p210, or ATM-deficient cells were
treated with etoposide for indicated periods of
time and analyzed by the comet assay. Olive
tail moment was measured by Komet 7 software
(Kinetic Imaging, Germany) for E and F. The arbi-
trary units are the same for both E and F.
nificantly more DNA damage than 3T3 cells (Figure 1F, striped cells using the radioresistant DNA synthesis (RDS) assay. The
RDS assay was originally described as an assay for disruption ofbars). Interestingly, the amount of DNA damage incurred was
comparable to ATM-deficient cells. These results demonstrate the ataxia-telangiectasia mutant (ATM) protein but has recently
been found to be an assay for disruption of an intra-S phasethat the increase in DNA double-strand breaks induced by BCR/
ABL is not restricted to hematopoietic cells and that the extent checkpoint (Painter and Young, 1980; Sorensen et al., 2003).
Cells were initially labeled with 14C thymidine to provide a controlof the phenotype is comparable to cells with a deficiency in
ATM, a known tumor suppressor. for DNA content. Cells were rested, treated with a genotoxic
agent, and then labeled with tritiated (3H) thymidine to determine
the amount of ongoing DNA synthesis after DNA damage. Re-BCR/ABL disrupts an intra-S phase checkpoint
and causes a RDS phenotype sults are displayed as the ratio of 3H/14C compared to untreated
cells, which are arbitrarily defined as 100% (Figure 2B, blackTo understand the mechanism whereby BCR/ABL could disrupt
DNA repair, we examined the effect of BCR/ABL expression on bars). As shown in Figure 2B, Ba/F3 pTET-ON p210 cells grow-
ing in IL3 show decreased DNA synthesis after treatment withcell cycle regulation after treatment of cells with etoposide. Ba/
F3 pTET-ON p210 cells were again grown in IL3 or treated -irradiation (white bars) or etoposide (striped bars), consistent
with an intact S phase checkpoint. However, when BCR/ABLwith doxycycline to induce BCR/ABL. Cells were treated with
a continuous exposure to etoposide for varying lengths of time is induced, the same cells show continued DNA synthesis after
DNA damage, showing that BCR/ABL expression disrupts theand analyzed for cell cycle distribution (Figure 2A). Both IL3-
stimulated cells and BCR/ABL-expressing cells demonstrated intra-S phase checkpoint leading to a RDS phenotype (Figure
2B, right side). To compare this phenotype to cells deficient ina G2/M cell cycle arrest between 6 and 18 hr after treatment
with etoposide (Figure 2A), consistent with an intact G2/M cell ATM, which have a known RDS phenotype, we studied fibroblast
cells (Figure 2C). NIH 3T3 fibroblasts showed decreased DNAcycle checkpoint. However, this arrest was seen several hours
earlier in BCR/ABL-expressing cells (compare closed circles to synthesis after treatment with -irradiation. In contrast, neither
3T3 cells expressing BCR/ABL nor ATM-deficient fibroblastsopen circles), suggesting the possibility of a defective S phase
checkpoint function in BCR/ABL-expressing cells, allowing cells showed an appropriate decrease in DNA synthesis, demonstra-
ting that BCR/ABL induces a phenotype similar to ATM-deficientto pass through S phase more quickly than control cells. To
determine if BCR/ABL-expressing cells had a defect in an intra- cells. These results demonstrate that BCR/ABL disrupts an in-
tra-S phase checkpoint.S phase checkpoint, we studied fibroblasts and hematopoietic
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Figure 2. BCR/ABL induces radioresistant DNA synthesis
A: Ba/F3 pTET-ON p210 cells growing in IL3 (open circles) or doxycycline to
induce BCR/ABL (closed circles) were plated in fresh media containing 10
M etoposide for indicated periods of time. Cells were fixed and stained with
propidium iodide and percent of cells in phases of cell cycle determined on
a FACStar using the ModFit software.
B: RDS assay was performed as described in methods on Ba/F3 pTET-ON
p210 cells growing in IL3 or doxycycline (BCR/ABL). Cells were either un-
treated (black bars) or treated with 20 Gy -irradiation (white bars) or 10
M etoposide (striped bars).
C: RDS assay was performed as described in methods on NIH 3T3 cells, NIH
3T3 cells stably expressing p210 BCR/ABL (BCR/ABL), or ATM-deficient cells,
GM02052 (ATM/). Untreated cells (black bars) are compared to cells
treated with 10 Gy -irradiation.
BCR/ABL translocates to the nucleus
after DNA damage
A critical question raised by the experiments above was how
Figure 3. BCR/ABL translocates to the nucleus after DNA damageBCR/ABL could affect DNA repair or cell cycle regulation when
A–F: NIH 3T3 cells stably expressing p210 BCR/ABL (A and D) or ABL/ fibro-it is sequestered in the cytoplasm. Either BCR/ABL could act
blasts transfected with p210 BCR/ABL (B and E) were either left untreatedindirectly through affecting signal transduction proteins that
(A and B) or treated with 10 M etoposide for 1 hr (D and E) and then
move to the nucleus (such as STAT proteins), or BCR/ABL could stained with antibody against ABL. As control for background staining, un-
act directly by translocating to the nucleus after DNA damage. transfected ABL/ cells were stained with anti-ABL antibody (C) and coun-
terstained with DAPI (F).Recent results suggested that BCR/ABL could move to the
G and H: Cells from a patient with CML in blast crisis were thawed and platednucleus (Vigneri and Wang, 2001); therefore, we examined local-
onto fibronectin-coated coverslips for 1 hr and then either not treated (G)
ization of BCR/ABL after treatment of cells with etoposide (Fig- or treated with etoposide (10 M) for 1 hr (H). Cells were stained with anti-
ure 3). Analysis of cells by immunofluorescence, 1–4 hr after ABL antibody (left) and counterstained with DAPI (center). Images were
overlayed (right).treatment with 10 M etoposide, showed consistent and com-
I–M: In a separate experiment, ABL/ fibroblasts were transfected withplete translocation of BCR/ABL from the cytoplasm to the nu-
pMSCV p210 BCR/ABL and transferred to fibronectin-coated coverslips.
cleus (compare Figures 3A and 3D). To eliminate background Cells were either untreated (I), treated with etoposide for 10 min (J), or
staining from endogeneous c-ABL, we then examined ABL/ treated with etoposide for 10 min, washed, and allowed to recover for 30,
60, or 120 min (K–M), respectively. Cells were fixed, permeabilized, andfibroblasts (Figures 3B, 3C, 3E, and 3F). Analysis of untrans-
stained with anti-ABL antibody.fected cells confirmed the absence of c-ABL (Figure 3C). Cells
were transiently transfected with BCR/ABL and treated with
etoposide. Staining of untreated cells confirmed the cytoplasmic
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localization of BCR/ABL (Figure 3B) and again BCR/ABL translo-
cated to the nucleus after treatment with etoposide (Figure 3E).
In order to demonstrate that BCR/ABL translocation was not
an artifact of high-level expression in fibroblast cells, we next
examined primary cells from patients with CML (Figures 3G and
3H). Mononuclear cells from peripheral blood were stored as
viable cells in DMSO. Cells were thawed, plated onto fibronec-
tin-coated coverslips in media, and examined on the day of
thawing. Analysis of cells that were not treated with etoposide
again confirmed the cytoplasmic localization of BCR/ABL (Fig-
ure 3G). After 1 hr of treatment with etoposide (10 M), BCR/
ABL again translocates to the nucleus (Figure 3H). Previous
work in CML has demonstrated that BCR/ABL is overexpressed
relative to endogeneous c-ABL and therefore most of the stain-
ing in Figure 3 represents primarily BCR/ABL (Wetzler et al.,
1993). Similar results were seen in a total of 3 patient samples,
one from chronic phase and two in blast crisis. In contrast,
CD34 hematopoietic stem cells and cells from patients with
acute myeloid leukemia (data not shown) demonstrated only
c-ABL nuclear staining without or with etoposide. Thus, BCR/
ABL translocation from the cytoplasm to the nucleus occurs
after genotoxic stress in both fibroblasts and primary patient
cells.
Previous reports and our own data (cf. Figure 1B) have
demonstrated that BCR/ABL expression in cytokine-dependent
cells provides protection against apoptosis that may be depen-
dent on activation of cytoplasmic signaling proteins including
Akt and BAD (Bedi et al., 1994; Neshat et al., 2000). However,
if BCR/ABL translocates to the nucleus after DNA damage, it
may not have access to appropriate substrates. c-ABL is known
to shuttle between the cytoplasm and the nucleus, although
Figure 4. BCR/ABL associates with ATM and alters signal transduction afterregulation of this shuttling is poorly understood (Taagepera et
DNA damage
al., 1998). In order to determine if BCR/ABL might shuttle in a
A: Parental Ba/F3 cells (lanes 1–3), Ba/F3 cells stably transfected with p210similar fashion, we performed a time course analysis of BCR/
BCR/ABL (lanes 4–6), Ba/F3 pTET-ON p210 cells growing in IL3 (lanes 7–9), or
ABL localization after DNA damage and repair in ABL/ fibro- washed free of IL3 and treated with doxycycline (lanes 10–12) were either
blasts. Initial results demonstrated that BCR/ABL translocates growing in log phase (lanes 1, 4, 7, and 10), treated with 10 M etoposide
for 90 min (lanes 2, 5, 8, and 11), or treated with etoposide for 90 min,to the nucleus within 10 min of addition of etoposide (Figure
washed, and incubated for an additional 90 min to allow for DNA repair3J). Earlier time points were not examined. Cells were then
(lanes 3, 6, 9, and 12). Cells were lysed and indicated proteins immunopre-
washed free of etoposide and localization of BCR/ABL followed cipitated. Immunoprecipitated proteins were separated by SDS-PAGE and
over time. BCR/ABL can be found in the cytoplasm within 30 blotted using anti-ABL antibody (top) or anti-ATM antibody (bottom).
B: Ba/F3 pTET-ON p210 cells growing in IL3 (lanes 1–4) or doxycycline (lanesmin of removal of etoposide and is completely cytoplasmic by
5–8) were treated with etoposide at different doses and times. ATM kinase2 hr after removal of etoposide (Figures 3K–3M). Thus, BCR/
activity was assayed as described in the Experimental Procedures.ABL translocation is rapid and reversible.
C: Ba/F3 pTET-ON p210 cells growing in IL3 (lanes 1–7) or doxycycline (lanes
8–14) were treated with etoposide (10 M) for indicated times. Cells were
BCR/ABL associates with ATM after DNA damage lysed and protein lysates were separated by SDS-PAGE and blotted onto
nitrocellulose. Blots were probed with antibody to phospho-Chk2 (top), thenbut does not affect ATM function
stripped and reprobed for total Chk2 (bottom).The translocation of BCR/ABL to the nucleus suggested that
BCR/ABL may disrupt DNA repair and cell cycle regulation di-
rectly. The nuclear protein c-ABL is known to associate with
ATM after DNA damage (Baskaran et al., 1997; Shafman et al.,
both the 145 kDa c-ABL band and the 210 kDa BCR/ABL protein1997), and disruption of ATM can cause a RDS phenotype. We
(Figure 4A, lanes 5 and 11). Association persisted but was de-therefore examined the association of BCR/ABL with ATM in
creased 90 min after withdrawal of etoposide (Figure 4A, lanesBa/F3 pTET-ON p210 cells after treatment with etoposide. Cells
6 and 12). Thus, association of BCR/ABL with ATM is induciblewere either grown without etoposide, treated with etoposide
by DNA damage and has a time course similar to the transloca-(10 M) for 90 min, or treated for 90 min, washed free of drug,
tion of BCR/ABL to the nucleus described above. Similar resultsand allowed to recover for 90 min (Figure 4). Examination of
were seen comparing parental Ba/F3 cells (Figure 4A, lanesuninduced pTET-ON p210 cells confirmed that DNA damage
1–3) with Ba/F3 cells stably transfected with BCR/ABL (Figureinduced association of ATM and c-ABL (Figure 4A, lanes 2
4A, lanes 4–6) as well as in one patient sample (data not shown).and 8). In BCR/ABL-expressing cells, immunoprecipitation with
However, when we examined ATM kinase activity, which isantibody against ATM and immunoblotting with an antibody
against ABL that recognizes both c-ABL and BCR/ABL revealed increased in cells after DNA damage, we saw no difference in
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Figure 5. BCR/ABL associates with ATR and dis-
rupts ATR-dependent signaling
A and B: Ba/F3 pTET-ON p210 cells were incu-
bated in IL3 (lanes 1 and 2) or doxycycline to
induce BCR/ABL expression (lanes 3 and 4). Cells
were either not treated (lanes 1 and 3) or treated
with 10 M etoposide for 2 hr. Cells were lysed
and lysates immunoprecipitated with indicated
antibodies. Immunoprecipitates were separated
by SDS-PAGE and analyzed by Western blot.
C: Ba/F3 pTET-ON p210 cells were grown in either
IL3 or doxycycline to induce BCR/ABL expression.
Cells were either not treated (lanes 1 and 8) or
treated with etoposide 10 M for the indicated
periods of time. Cells were lysed and analyzed
by Western blot using an antibody specific for the
phosphorylated form of Chk1. Blot was stripped
and reprobed for total Chk1 expression.
D: Cells were treated as above. In addition, some
cells were maintained in both IL3 and doxycy-
cline (lanes 9–12). Cells were not treated (lanes
1, 5, and 9) or treated with etoposide for the
indicated periods of time and then lysed and
analyzed by immunoprecipitation using anti-
cdc7 antibody followed by Western blotting for
Dbf4.
ATM kinase activity in cells growing in IL3 or expressing BCR/ and the immunoprecipitation with anti-ABL antibody and blot-
ting with anti-ATR antibody demonstrated the same result (Fig-ABL (Figure 4B) using a GST-p53 1-101 fusion protein as sub-
strate. Likewise, we saw no difference in phosphorylation of the ure 5B). Thus, BCR/ABL associates with ATR after treatment
of cells with etoposide.ATM substrate, Chk2, in cells under either set of conditions
(Figure 4C). Thus, although BCR/ABL, like c-ABL, can associate To determine if BCR/ABL affects Chk1 activity, we examined
phosphorylation of Chk1 after DNA damage (Figure 5C). Chk1with ATM after DNA damage, it does not appear to alter ATM
function. is a serine threonine kinase activated by ATR after DNA damage
(Liu et al., 2000). Cells were induced to express BCR/ABL, and
control cells and BCR/ABL-expressing cells were treated withBCR/ABL associates with ATR and disrupts ATR-
dependent signal transduction events etoposide for varying periods of time as indicated. Phosphoryla-
tion of Chk1 was examined by Western blotting using an anti-Although first described in association with ATM deficiency, the
RDS phenotype has recently been described in cells deficient body specific for Chk1 phosphorylated on serine 345, the site
where ATR phosphorylates the protein. Phosphorylation of Chk1in Chk1, a critical regulatory substrate of the ataxia telangiecta-
sia and rad 3-related (ATR) protein. ATR is a homolog of ATM was induced normally in the IL3-stimulated cells (Figure 5C,
lanes 1–7). However, in the BCR/ABL-expressing cells, onlywith a critical role in regulating chromosomal stability (Brown
and Baltimore, 2000, 2003; Heffernan et al., 2002). We therefore minimal phosphorylation of Chk1 is seen (Figure 5, lanes 8–14).
This experiment was repeated multiple times, and no substantialexamined cells for an etoposide inducible association of BCR/
ABL and ATR (Figures 5A and 5B). Ba/F3 pTET-ON p210 cells phosphorylation of Chk1 was detected at any time point. This
result suggested to us that the RDS phenotype seen in BCR/were grown in IL3 (Figure 5A, lanes 1 and 2) or in doxycycline
to induce expression of BCR/ABL (Figure 5A, lanes 3 and 4). ABL-expressing cells may represent a defect in ATR signaling,
rather than a defect in ATM signaling.Cells were either untreated or treated with etoposide and then
lysed. Immunoprecipitation of lysates with an anti-ATR antibody A recent report has described activation of ATR by etopo-
side-induced DNA damage (Costanzo et al., 2003). The authorsand subsequent blotting with an anti-ABL antibody demon-
strated an association of ATR and BCR/ABL only after treatment describe an ATR-dependent “etoposide checkpoint” that is me-
diated through regulation of the cdc7/Dbf4 complex. To exam-of cells with etoposide (Figure 5A, lane 4). Induction of BCR/
ABL was confirmed in the same lysates (Figure 5A, lower panel) ine regulation of this complex, we examined Ba/F3 pTET-ON
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p210 cells again after treatment of cells with etoposide. Cells
growing in IL3 without etoposide showed activation of the com-
plex as shown by co-immunoprecipitation of cdc7 and Dbf4
(Figure 5D, lane 1). After treatment with etoposide, however, the
complex is disrupted, demonstrating an intact ATR-dependent
signaling response to etoposide in the cells growing in IL3. On
the other hand, when cells are induced to express BCR/ABL,
the complex is not dissociated after treatment with etoposide
(Figure 5D, lanes 5–8). To ensure that it is the induction of BCR/
ABL that disrupts the ATR checkpoint and not withdrawal of
IL3, we also examined cells in which BCR/ABL expression is
induced but IL3 was not withdrawn (Figure 5D, lanes 9–12).
These cells showed the same lack of ability to disrupt the cdc7-
Dbf4 complex, showing that it is the presence of BCR/ABL and
not the absence of IL3 that disrupts ATR.
BCR/ABL Disrupts ATR Signaling
in Primary Patient Cells
To ensure that the disruption of ATR signaling in BCR/ABL-
expressing cells is not an artifact of overexpression in cell lines,
we again examined primary patient cells (Figure 6A). Initially, in
order to determine the relative levels of expression of BCR/ABL
in cell lines compared to primary cells, we prepared lysates
from both cell lines and primary patient samples. Patient sam-
ples (Figure 6A, lanes 5–14) were obtained from CML patients
with different stages of disease and with different percentage
blasts as indicated. Expression of BCR/ABL in hematopoietic
cell lines was again induced by addition of doxycycline in the
presence or absence of interleukin 3 (Figure 6A, lanes 1–3).
Expression in the absence of IL3 and the presence of doxycy-
cline was highest and equivalent to expression in stable fibro-
blast cell lines (Figure 6A, lanes 3 and 4). Expression in CML
blast crisis samples was variable and ranged from equivalent
to expression in cell lines (cf. sample 203, which expresses
p190 BCR/ABL, and sample 276) to 10-fold less (sample 154,
Figure 6A, lane 5). Proteolysis during preparation of protein
lysates from primary myeloid cells is a common problem, and
the lower molecular weight bands seen in multiple samples
probably represent a combination of c-ABL staining and degra-
dation of BCR/ABL. Overall, this experiment demonstrates that
expression of BCR/ABL in these cell lines is equivalent to orFigure 6. BCR/ABL associates with ATR and disrupts ATR signaling in primary
CML cells greater than expression in patient samples.
To determine the effect of BCR/ABL on ATR in primaryPatient samples were rapidly thawed and plated in media for 1 hr prior to
initiating experiments. cells, we examined cells from patients with AML or CML for
A: Ba/F3 pTET-ON p210 cells (lanes 1–3) were grown in the presence of IL3 association of BCR/ABL and ATR. In two separate patient sam-
and doxycycline for 24 hr as indicated. 3T3p210 cells were harvested from
ples (Figure 6B, lanes 3–6), immunoprecipitation of ATR andsubconfluent plates. Patient samples were thawed and immediately lysed.
blotting with anti-ABL antibody demonstrated an etoposide-Lysates were immunoprecipitated with antibody against c-ABL (8E9); immu-
noprecipitated proteins were separated by SDS-PAGE and blotted with the induced association of the two proteins. Interestingly, this asso-
same anti-ABL antibody. Abbreviations: BC, CML blast crisis; CP, CML ciation was seen both in a patient expressing the p210 isoform
chronic phase; AP, CML accelerated phase; MD, myelodysplastic syn- of BCR/ABL studied in our cell line experiments and in a patientdrome; AML, acute myeloid leukemia. Percentage blasts is based on values
with the p190 isoform (pt. 203, Figure 6B, lanes 5 and 6). Ofobtained from clinical specimens analyzed by the Hospital of the University
of Pennsylvania Pathology Department. note, in these human cells, the anti-ATR immunoprecipitate also
B: Cells were either not treated or treated with etoposide (10 M) for 1 hr. contained c-ABL, which was not seen in our experiments in the
Cells were lysed and indicated proteins immunoprecipitated. Immunopre- murine Ba/F3 cells (compare Figure 6B, lane 2, to Figure 5A,
cipitated proteins were analyzed by Western blotting.
C: Cells were treated with etoposide (10 M) for the indicated periods of
time and then harvested and lysed. For analysis of Chk2 phosphorylation,
total Chk2 protein was immunoprecipitated and analyzed using the anti-
phospho-ATM/ATR substrate antibody (Cell Signaling). Blot was stripped and
reprobed with antibody against total Chk2. For analysis of Chk1 phosphory- D: Patient samples and parental Ba/F3 cells were incubated in appropriate
lation, protein lysate was analyzed by Western blotting using an antibody media and either not treated or treated with etoposide (10 M) for 1 hr.
specific for the phosphorylated form of Chk1. Blot was again stripped and Cells were lysed and anti-cdc7 immunoprecipitates performed and associ-
reprobed for expression of total Chk1. ation with Dbf4 analyzed by Western blotting.
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lane 2). Whether this represents a difference in species or be-
tween the cell line and primary cells is not clear. These results
were confirmed by immunoprecipitating with anti-ABL antibody
and blotting with anti-ATR antibody (Figure 6B, lower panel).
Uniform expression of ATR was also demonstrated in the lysate
fractions of this blot (Figure 6B, lower panel, lanes 7–12). Thus,
this experiment confirms that ATR associates with BCR/ABL in
primary patient cells. To determine if ATR is functionally active
in CML patient cells, we examined signal transduction down-
stream of ATR. Cells from a patient with CML were thawed and
allowed to recover. Cells were then either not treated (Figure
6C, lane 1) or treated with etoposide (10 M) for the indicated
amounts of time. Chk2 phosphorylation was again examined by
immunoprecipitating and blotting for the phosphorylated form of
the protein as in Figure 5 above. Consistent with the results
above, and suggesting an intact ATM pathway, Chk2 is phos-
phorylated in these primary cells after treatment with etoposide.
In contrast, no phosphorylation of Chk1 was seen at any of
the time points examined (Figure 6C, lower panels). Finally,
we examined CML and AML patient samples for the ability to
inactivate cdc7 after treatment with etoposide. AML cells (Figure
6D, lanes 7 and 8) showed association of cdc7 and Dbf4 in the
absence of etoposide, which was not present after treatment
of cells. In contrast, three CML patient samples (Figure 6D,
Figure 7. Overexpression of ATR in BCR/ABL-expressing cells reverts the DNAlanes 1–6) showed association of cdc7 and Dbf4 in the absence
damage phenotypeor presence of etoposide. This result confirms that BCR/ABL
A: 3T3 cells stably expressing p210 BCR/ABL were transfected with FLAG-inhibits ATR signaling in response to etoposide in primary CML
tagged ATR construct. 48 hr after transfection, control 3T3 cells (lanes 1 andpatient samples.
2), nontransfected 3T3 p210 cells (lanes 3 and 4), or transfected cells (lanes
5 and 6) were either not treated (lanes 1, 3, and 5) or treated with etoposide
Overexpression of ATR in BCR/ABL-expressing cells (10 M) for 90 min (lanes 2, 4, and 6). Cells were lysed and analyzed for
expression of FLAG-tagged ATR (top), phosphorylated Chk1 (middle), orreverts the DNA damage phenotype
total Chk1 (lower).In order to determine if inhibition of ATR function causes the
B: Cells prepared as in A were analyzed using the comet assay. ATM-defi-DNA damage phenotype described above, we hypothesized cient cells were used as a control for the assay.
that the interaction of BCR/ABL with ATR is stochiometric and
that overexpression of ATR would lead to free ATR, which would
be able to activate the signaling pathway after DNA damage.
To test this hypothesis, we transfected NIH 3T3 cells, which Discussion
stably express p210 BCR/ABL with a FLAG-tagged ATR cDNA
and examined cells for the response to DNA damage (Figure 7). A role for BCR/ABL in altering the cellular response to DNA
Expression of the FLAG-tagged ATR was confirmed by Western damage has been previously hypothesized (Deutsch et al.,
blotting (Figure 7A, lanes 5 and 6). In these fibroblast cell lines, 2001). We demonstrate that BCR/ABL expression leads to an
we confirmed that treatment of wild-type fibroblasts with etopo- increase in the amount of DNA double-strand breaks after treat-
side induces the phosphorylation of Chk1 (Figure 7A, lane 2). ment of cells with etoposide and a disruption of an intra-S phase
In the stably expressing BCR/ABL lines, Chk1 is not phosphory- checkpoint. Our results demonstrate that these are direct effects
lated after treatment with the drug as expected (Figure 7A, of BCR/ABL as BCR/ABL translocates to the nucleus after DNA
lane 4). However, when ATR is overexpressed and the cells are damage, placing the protein in the appropriate cellular compart-
treated with etoposide, Chk1 phosphorylation is again seen ment for disrupting DNA repair processes. Translocation of
(Figure 7A, lane 6), demonstrating that overexpression of ATR BCR/ABL is rapid and reversible and occurs both in fibroblasts
reconstitutes ATR signaling in response to DNA damage in BCR/ and primary patient cells. In addition, we demonstrate that BCR/
ABL-expressing cells. To determine how this would affect DNA ABL associates with ATR after treatment of cells with etoposide
damage, we again performed the comet assay (Figure 7B). Un- and disrupts ATR-dependent signal transduction. Disruption of
treated cells showed no differences in spontaneous DNA dam- ATR is demonstrated by the decrease in the phosphorylation
age whether they did or did not express BCR/ABL or ATR. BCR/ of Chk1 and the lack of inactivation of the cdc7/Dbf4 complex,
ABL-expressing cells again show an increase in DNA damage which is required for the replication arrest induced by etoposide.
after 90 min treatment with etoposide (Figure 7B, striped bars). This is an entirely novel mechanism of oncogenesis by BCR/ABL.
However, when ATR is overexpressed, little DNA damage is There has been controversy as to whether BCR/ABL in-
seen at this time point, demonstrating that ATR overexpression creases or decreases DNA damage and repair processes. Skor-
blocks the effect of BCR/ABL to increase DNA damage seen ski and colleagues have proposed that BCR/ABL increases the
in BCR/ABL-expressing cells. This experiment demonstrates expression of Rad51 and leads to an increase in homologous
that the ability of BCR/ABL to increase DNA damage is depen- recombination repair that leads to chemotherapy resistance
(Majsterek et al., 2002; Slupianek et al., 2001). Neither we (datadent on blocking the function of ATR.
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to check DNA replication (Figure 8). Applied to our model, these
results suggest that the phenotype we have described may be
restricted to the cellular response to etoposide-induced DNA
damage only, to agents that leave single strand intermediates,
or through effects that lead to stalled replication forks that may
be repaired through a similar mechanism. In this regard, how-
ever, the RDS phenotype is present in BCR/ABL-expressing
fibroblasts after treatment with IR and IR also leads to increased
DSB, so the results are not exclusive to etoposide alone (Figure
2). Future studies will need to address whether BCR/ABL dis-
rupts the response to DNA damage only through this pathway
or affects the response to other agents as well.
The demonstration that BCR/ABL disrupts the ATR signaling
pathway and causes an RDS phenotype may have profound
implications for chromosomal stability in chronic myeloid leuke-
mia. ATR is a member of a family of proteins that includes ATM
and DNA PKcs (Abraham, 2001). Several reports confirm the
critical importance of the intra-S phase checkpoint in main-
taining genomic stability (Kolodner et al., 2002; Ye et al., 2003).
Thus, disruption of ATR signaling, even transiently at critical
moments when cells contain DNA double-strand breaks, may
Figure 8. Effect of BCR/ABL on an ATR-dependent cell cycle checkpoint
predispose cells to the formation of chromosomal translocations
Left: Model is based on that proposed by Costanza et al. (2003). In cells or deletions. A novel aspect of our results is the transient inhibi-growing in normal cytokines, etoposide-induced DNA damage triggers a
tion of ATR function associated with a DNA damage-inducedDNA double-strand break, which is processed to a single strand end. This
triggers binding of both RPA and ATR and activation of ATR. ATR phosphory- redistribution of BCR/ABL from the cytoplasm to the nucleus.
lates Chk1, which inactivates the cdc7/Dbf4 complex, leading to de- Although the mechanism of this translocation is unclear, this
creased loading of cdc45 in the pre-RC. finding is consistent with the results for c-ABL and BCR/ABL
Right: BCR/ABL binds to ATR. Double-headed arrow indicates that binding
previously described (Taagepera et al., 1998; Vigneri and Wang,may happen on or off DNA. Such binding prevents ATR from activating
2001). Given the lethality of an ATR null phenotype, it is perhapsChk1. The cdc7/Dbf4 complex remains active and replication proceeds
inappropriately. Bottom of figure indicates that collision of the replication not surprising that BCR/ABL does not constitutively associate
complex with the topoisomerase II/etoposide complex on DNA may lead with ATR. Future experiments will be required to fully define the
to further DNA double-strand breaks.
consequences of the DNA damage-induced association of ATR
and BCR/ABL.
In conclusion, we have found that BCR/ABL translocates
from the cytoplasm to the nucleus after genotoxic stress. Fur-not shown) nor others have reproduced the increase in Rad
thermore, BCR/ABL expression increases DNA double-strand51 expression described by Slupaniek, and we do not see a
damage after etoposide and leads to a defect in an intra-Ssignificant alteration in chemotherapy resistance comparing
phase checkpoint, causing a radioresistant DNA synthesiscells growing in IL3 alone versus BCR/ABL-expressing cells in
(RDS) phenotype. This represents the first detailed descriptionthe absence of IL3 (Deutsch et al., 2003). However, experimental
of disruption of a cell cycle checkpoint by BCR/ABL. Finally,conditions, particularly the presence or absence of IL3 in the
BCR/ABL disrupts ATR-dependent signal transduction afterculture, the use of different cell lines, and the type of DNA-
treatment with etoposide. Future experiments will determine ifdamaging agent may alter the results of the two experiments.
BCR/ABL expression leads to genomic instability, which mayOn the other hand, Deutsch and colleagues have demonstrated
lead to CML blast crisis.that BCR/ABL-expressing cells have an increase in sister chro-
matid exchanges and chromosomal translocations after treat- Experimental procedures
ment with IR. Although we have not examined SCE or transloca-
tions directly, these would be predicted to be increased in cells Cells and constructs
Ba/F3 pTET-ON p210 cells have been previously described (Klucher et al.,with disruption of ATR function and an increase in DNA double-
1998). ABL/ 3T3 cells were a kind gift of Dr. Warren Pear (University ofstrand breaks. In fact, the results of Deutsch and colleagues
Pennsylvania) and were derived from ABL/ murine embryo fibroblastsare entirely consistent with the model we propose (cf. Figure 8
(MEFs). GM02025D cells are a human fibroblast line derived from a patient
and below), although we describe a different mechanism of DNA deficient in ATM and were obtained from the Coriell Cell repository (Camden,
damage. Overall, our results support a model that BCR/ABL NJ). Cells from patients with CML and AML were obtained from the Stem
has a direct role in increasing DNA damage, which may eventu- Cell and Leukemia Core Facility at the University of Pennsylvania Cancer
Center. Pathologic diagnosis including stage of CML was obtained from theally lead to CML blast crisis.
bone marrow biopsy reports as performed by the Hospital of the UniversityAnother significant difference in our experiments compared
of Pennsylvania. pMSCV GFP and pMSCV p210 BCR/ABL IRES GFP wereto other work involves the use of etoposide. Costanzo et al. (2003)
a kind gift of Dr. Warren Pear. Nucleotides 1–101 of p53 were amplified bydemonstrate that the early response to etoposide-induced DNA
PCR and cloned into the EcoRI and Bam HI sites of GST expression vector
damage is dependent on ATR. ATR acts to inactivate Cdc7, a pGEX-2T (Amersham Biosciences) for ATM kinase assays. FLAG-tagged
cell cycle kinase necessary for the formation of the prereplica- ATR cDNA was a kind gift of Stuart Schreiber and Karlene Cimprich and
has been previously described (Cliby et al., 1998).tion complex (pre-RC). Thus, ATR acts in response to etoposide
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Immunofluorescence containing ice-cold alkaline solution (50 mM NaOH, 1 mM disodium EDTA
Where indicated, cells were transfected using either FuGene 2000 or Lipofect- [pH 12.5]) and incubated for 45 min in the dark. Electrophoresis was carried
amine reagent (ABL/ cells) according to the manufacturer’s directions. out for 25 min at 18 V (0.6 V/cm) and 250 mA in the dark. Slides were
Constructs were either pMSCV-GFP control or pMSCV BCR/ABL p210/GFP. removed, and 1 ml of neutralizing solution (0.5 M Tris-HCl [pH 7.5]) was
Cells were transfected and incubated for 24 hr. Cells were then trypsinized added and incubated for 10 min. Each slide was rinsed twice with 1 ml
and replated on fibronectin-coated coverslips. Cells were incubated in ap- of phosphate-buffered saline (PBS) and allowed to dry overnight at room
propriate media for an additional 24 hr on coverslips and then treated as temperature. Slides were stained with propidium iodide (2.5 g/ml), and
indicated in each figure. Cells were fixed with paraformaldehyde, permeabil- comets were analyzed using a Nikon DIAPHOT TDM inverted epifluorescent
ized, and stained with antibodies against ABL at 1:200 dilution (8E9, Phar- microscope (consisting of a high-pressure mercury vapor light source, a 580
mingen) and anti-mouse Cy 5 at 1:1000 (Molecular Probes), and then coun- nm dichromic mirror, 510 to 560 nm excitation filter, and 590 nm barrier
terstained with the DNA dye, DAPI (10 nM). Cells were visualized using a filter) at 20magnification. 50–100 cells were analyzed per slide using Komet
confocal microscope fitted with two lasers. Data was analyzed using Confo- Assay software (Kinetic Imaging, Liverpool, UK) for olive tail moment, and
cal Assistant software provided by Bio-RAD. Primary cell samples were mean and standard deviation for each experiment were calculated using
thawed and plated directly onto fibronectin-coated coverslips for 1 hr prior Microsoft Excel.
to incubation with etoposide.
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